Brief: Acura Pharma reports topline results from Nexafed extended clinical study
23/03/2015 10:01
March 23 (Reuters) - Acura Pharmaceuticals Inc ACUR.O : * Reports successful topline results from Nexafed(R) extended-release clinical study * Says intends to request pre-ind meeting with the US food and drug administration to review study data and discuss complete development program * Source text for Eikon ID:nMKW33Pz0a * Further company coverage ACUR.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Acura Pharmaceuticals
See all newsBrief: Acura Pharmaceuticals Received A $250,000 Loan From Abuse Deterrent Pharma, LLC on October 11
Brief: Acura Pharmaceuticals Inc Receives $200,000 Loan From Abuse Deterrent Pharma
Brief: Acura Pharmaceuticals Received $250,000 Loan From AD Pharma For Operations Through End Of April 2023
Brief: Acura Pharmaceuticals, AD Pharma Amend License to LIMITx LTX-03
Insight: Novavax bosses cash out for $46 mln with COVID-19 vaccine trials still under way